Tag: Mind Cure - Psychedelic Alpha

Explore psychedelic drug development via our Q1'25 🎯 Bullseye Chart.

Read more about the article MINDCURE Provides Update on Strategic Review

MINDCURE Provides Update on Strategic Review

Post published:March 16, 2022
Post category:Press Release

Read more about the article MINDCURE Achieves Key Development Milestone for Novel Ibogaine Program

MINDCURE Achieves Key Development Milestone for Novel Ibogaine Program

Post published:March 2, 2022
Post category:Press Release

Read more about the article MINDCURE Hires Dr. Clare Purvis from Headspace to the position of Chief Product Officer to Advance Mental Health Digital Therapeutics Platform

MINDCURE Hires Dr. Clare Purvis from Headspace to the position of Chief Product Officer to Advance Mental Health Digital Therapeutics Platform

Post published:February 3, 2022
Post category:Press Release

Read more about the article MINDCURE Announces Financial Results for the Second Quarter of Fiscal 2022

MINDCURE Announces Financial Results for the Second Quarter of Fiscal 2022

Post published:January 25, 2022
Post category:Press Release

Read more about the article MINDCURE Announces Certification of HIPAA Compliance, Bringing iSTRYM Closer to Commercial Deployment in the Second Quarter of 2022

MINDCURE Announces Certification of HIPAA Compliance, Bringing iSTRYM Closer to Commercial Deployment in the Second Quarter of 2022

Post published:December 16, 2021
Post category:Press Release

Read more about the article MINDCURE Appoints Dr. Doron Sagman as Chief Medical Officer

MINDCURE Appoints Dr. Doron Sagman as Chief Medical Officer

Post published:December 14, 2021
Post category:Press Release

Read more about the article MINDCURE Provides Update on Studies and Clinical Trials

MINDCURE Provides Update on Studies and Clinical Trials

Post published:November 4, 2021
Post category:Press Release

Read more about the article MINDCURE Signs LOI with Awakn Life Sciences to Distribute Ketamine Protocol for Alcohol Use Disorder into Clinics Across United States and Canada through iSTRYM, MINDCURE’s Digital Therapeutics Platform

MINDCURE Signs LOI with Awakn Life Sciences to Distribute Ketamine Protocol for Alcohol Use Disorder into Clinics Across United States and Canada through iSTRYM, MINDCURE’s Digital Therapeutics Platform

Post published:October 28, 2021
Post category:Press Release

Read more about the article MINDCURE Announces Financial Results for the First Quarter of Fiscal 2022

MINDCURE Announces Financial Results for the First Quarter of Fiscal 2022

Post published:October 26, 2021
Post category:Press Release

Read more about the article MINDCURE Announces Commencement of Trading on the OTCQX Best Market

MINDCURE Announces Commencement of Trading on the OTCQX Best Market

Post published:September 30, 2021
Post category:Press Release

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.